Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 67, Number 8, October 24, 2006
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christensen, J.
Right arrow Articles by Sidenius, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christensen, J.
Right arrow Articles by Sidenius, P.
Related Collections
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
NEUROLOGY 2006;67:1497-1499
© 2006 American Academy of Neurology
Brief Communications

Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy

Jakob Christensen, MD, PhD, Anne Sabers, MD and Per Sidenius, MD, PhD

From the Departments of Clinical Pharmacology (J.C.) and Neurology (J.C., P.S.), Aarhus University Hospital, Aarhus, Denmark; and Department of Neurology (A.S.), Glostrup University Hospital, Glostrup, Denmark.

Address correspondence and reprint requests to Dr. Jakob Christensen, Department of Neurology, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark; e-mail: Jakob{at}farm.au.dk.

We assessed the concentration of the oxcarbazepine metabolite 10-hydroxycarbazepine (MHD) in nine pregnancies among seven women before, during, and after pregnancy. The mean dose-corrected concentration of MHD was decreased during pregnancy (analysis of variance, p = 0.0016), being 72% (SD = 13%) in the first trimester, 74% (SD = 17%) in the second trimester, 64% (SD = 6%) in the third trimester, and 108% (SD = 18%) after pregnancy vs the dose-corrected concentration before pregnancy.

Disclosure: The authors report no conflicts of interest.

Received February 24, 2006. Accepted in final form June 29, 2006.




This article has been cited by other articles:


Home page
 NeurologyHome page
K. J. Meador, P. B. Pennell, C. L. Harden, J. C. Gordon, T. Tomson, P. W. Kaplan, G. L. Holmes, J. A. French, W. A. Hauser, P. G. Wells, et al.
Pregnancy registries in epilepsy: A consensus statement on health outcomes
Neurology, September 30, 2008; 71(14): 1109 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
T. Tomson and V. Hiilesmaa
Epilepsy in pregnancy
BMJ, October 13, 2007; 335(7623): 769 - 773.
[Full Text] [PDF]